The Journal of
Clinical Psychiatry

Empowering mental health professionals with peer-reviewed psychiatric research and insights

Back to top Open menu arrow
Current Issue Archives Authors Reviewers

Just Published

JCP
Ketamine-Associated Uropathy in Therapeutic Contexts: Reply to Abdelrahman
Letter to the Editor

January 26, 2026

Dr Andrade responds to a letter commenting on his recent review of ketamine-associated uropathy in therapeutic and nontherapeutic settings.
JCP
Next-Step Treatment Options for Treatment-Resistant Depression
Consensus Statement

January 21, 2026

Strong consensus emerged for augmentation with second-generation antipsychotics, TMS, and ketamine/esketamine in the base vignette. Preferences shifted to include non-augmentative antidepressants and ECT based on patient characteristics.
, , , et al
JCP
How Many Criteria Should be Required to Define the DSM-5 Mixed Features Specifier in Depressed Patients?
Original Research

January 21, 2026

In a study of 459 depressed patients, results did not support lowering the DSM-5-TR diagnostic threshold for the mixed features specifier from 3 to 2 criteria.
,

Insightful. Evidence-based. Human-centered.

The Journal of Clinical Psychiatry Podcast

Explore the science, practice, and human side of mental health care. Hosted by Dr. Ben Everett, Senior Scientific Director at Physicians Postgraduate Press, the series brings together leading voices in psychiatry, neuroscience, and behavioral medicine to discuss the evidence shaping clinical care today.

Each episode features thoughtful conversations with JCP authors, academic experts, and frontline clinicians exploring disorders across the mental health continuum, from schizophrenia and mood disorders to anxiety, depression, and sleep-related conditions. By bridging research and real-world practice, the podcast delivers insights that empower psychiatrists, nurse practitioners, physician associates, and primary care clinicians to deliver better care for patients with mental illness.

Learn More

 

Explore Special Sections

Focus on Childhood and Adolescent Mental Health Early Career Psychiatrists Focus on Geriatric Psychiatry Focus on Psychotherapy Focus on Psychosis Focus on Suicide Focus on Women’s Mental Health

Vol 87 • 2026 • Number 1

Read the Current Issue

ASCP Corner

Rethinking Amisulpride: Could N-Methylation Result in a New and Even Better Antipsychotic?

Original Research

How Many Criteria Should be Required to Define the DSM-5 Mixed Features Specifier in Depressed Patients?

Meta-Analysis

Effectiveness of Peer-Administered Interventions for Perinatal Depression or Anxiety

Original Research

Innovation in Psychiatric Drug Development: A Quantitative Analysis of FDA-Approved Psychiatric Drugs, 2012–2024

Brief Report

Exercise Reduces Dysphoria in Clinical High-Risk for Psychosis: A Randomized Controlled Trial

Clinical and Practical Psychopharmacology

Pregabalin in Pregnancy: Major Congenital Malformations, Other Birth Outcomes, and Neurodevelopmental Outcomes
View current Issue

Original Research

JCP
Geographic Differences in Cannabis Use and Cannabis Use Disorder in the US Veteran Population
Original Research

January 19, 2026

Significant regional differences were observed in cannabis use and cannabis use disorder (CUD). Veterans in the Pacific region had the highest rates of cannabis use and CUD.
, , , et al
JCP
Identifying Optimal Thresholds for Early Opioid Use Frequency in Predicting Buprenorphine Outcomes
Original Research

January 14, 2026

Even very low levels of opioid use in the first 2–3 weeks of buprenorphine treatment signal risk for poor outcomes.
, , , et al
JCP
Video Therapy Habit Reversal Training for Body-Focused Repetitive Behaviors
Original Research

January 12, 2026

Large treatment effects and improvements across the lifespan for trichotillomania and excoriation disorder suggest this delivery format may address barriers to evidence-based care.
, , , et al

Review Articles

JCP
Burnout in Psychiatric Doctors Before and After the COVID-19 Pandemic
Meta-Analysis

September 29, 2025

The prevalence of burnout was 37.5% prior to the COVID-19 pandemic and 32.0% following the pandemic.
, ,
JCP
Treating PTSD in Military Populations
Meta-Analysis

March 24, 2025

Integrating psychotherapies and pharmacotherapies may address multiple dimensions of PTSD more effectively than monotherapies.
, , , et al
JCP
Changes in Cognition in Patients With Schizophrenia
Meta-Analysis

September 25, 2024

Only marginal improvements in cognition were seen over time; the greatest were achieved for patients with an illness duration shorter than 10 years.
, , , et al
JCP
Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia
Review Article

August 21, 2024

Patients with schizophrenia and cognitive impairment had a 100% increase in relapse-related hospitalizations and ER visits versus patients with no (or only mild) cognitive impairment.
, , , et al
JCP
Cognitive Effects of ECT in Schizophrenia: A Review
Review Article

June 5, 2024

ECT was not associated with any significant cognitive deficits in people with treatment-resistant schizophrenia across global cognition, attention, language, visuospatial function, and executive function domains. The majority of studies…
,
JCP
Interpersonal Psychotherapy for PTSD: A Critical Review
Review Article

May 29, 2024

This critical review will give clinicians confidence in considering IPT as an alternative to exposure treatments for posttraumatic stress disorder.

Read articles from ASCP Corner

ASCP Corner

Letters to the Editor

JCP
Reframing the Discussion on Finasteride and Neuropsychiatric Safety
Letter to the Editor

December 17, 2025

The authors comment on a recent article by Brezis, who argues that finasteride is causally linked to depression, suicidality, and other neuropsychiatric reactions.
,
JCP
Finasteride-Induced Neuropsychiatric Reactions: No Room for Complacency
Letter to the Editor

December 17, 2025

Dr Brezis replies to a letter by Tringali and Tringali regarding his recent article.
JCP
Burnout in Psychiatric Doctors Before and After COVID-19: A Critical Commentary
Letter to the Editor

December 1, 2025

The authors comment on a recent meta-analysis by Johnson and colleagues.
,
JCP
Exposure Therapy for Perinatal OCD: Navigating Evidence and Discomfort
Letter to the Editor

November 17, 2025

Although patients and providers must be prepared for the temporary distress associated with exposure and response prevention, it remains the most effective nonpharmacologic treatment for OCD.
, ,
JCP
From Today’s Observations to Tomorrow’s Standards in Women’s Psychiatry
Letter to the Editor

November 3, 2025

The authors comment on a recent study of treatment use and preference in women with mood disorders.
, ,
JCP
Context Matters in Treatment Preference of Women With Mood Disorders: Reply to Świeczkowski et al
Letter to the Editor

November 3, 2025

The authors reply to Świeczkowski and colleagues’ letter regarding their recent study
,

Commentaries

JCP
Precision Medicine for Suicide Prevention: It’s Time to Take the Next Step
Commentary

December 22, 2025

The authors recommend moving toward a precision medicine approach to suicide prevention that considers the person, their circumstances and biology, treatment delivery context, and conditions that contribute to the…
, , , et al
JCP
The Goldilocks Problem: Balancing Internal Validity with Generalizability in Clinical Trials
Commentary

November 26, 2025

The author discusses a recent analysis by Zimmerman and Snyder focusing on the generalizability of PTSD treatment trials.
JCP
MAOI Antidepressants: A History Being Rewritten
Commentary

November 26, 2025

Members of the International MAOI Expert Group discuss historical use of MAOIs, consider their efficacy and safety, and underscore the importance of reassessing their place in treatment algorithms.
, , , et al
JCP
Gender-Affirming Perinatal Psychiatry for Transgender and Gender Diverse People
Commentary

November 10, 2025

Considerations for providing perinatal psychiatric care to transgender and gender diverse patients are addressed
, ,
JCP
Beyond the Boxed Warning: A Call for Regulation of Psychiatry’s Most Teratogenic Drug
Commentary

October 6, 2025

The authors assert that while valproate remains invaluable for certain severe conditions, the high risk of teratogenicity means stringent safeguards are needed to regulate its use by individuals capable…
, , , et al
JCP
Why Getting Major Depression Right Matters—For Mothers, Babies, and All of Us
Commentary

September 24, 2025

Commenting on an FDA panel discussion on SSRI use during pregnancy, Dr Payne emphasizes the importance of precision when discussing treatments for mental health conditions.

More JCP Articles

JCP
Thank You to the JCP Community
Editorial

January 19, 2026

Marlene P. Freeman, Editor in Chief, expresses gratitude to JCP’s editors, editorial board members, peer reviewers, authors, and readers.
JCP
The Psychedelic Renaissance and Treatment-Resistant Depression with David Feifel, MD, PhD
Podcast

January 13, 2026

,
JCP
Digital Cognitive Intervention in Older People at Risk of Dementia
Original Research

January 7, 2026

A 6-month digital multi-domain intervention enhanced general cognitive function and visuospatial memory and reduced loneliness in older adults at high risk for dementia.
, , , et al
JCP
Rechallenge of Lamotrigine After Rash: A Systematic Review
Systematic Review

December 31, 2025

Lamotrigine has been rechallenged safely in select cases, but it is critical to confirm that the initial rash did not have specific features of a severe rash in order…
, , , et al
JCP
Psychiatric Hospitalization and Suicide Attempts in Healthcare Professionals
Original Research

December 31, 2025

Daily suicidal ideation and severe sleep disturbances were found to synergistically elevate suicide risk among healthcare professionals.
, , , et al
JCP
Dr Michael Asbach on the Evolution of PAs in Psychiatry
Podcast

December 30, 2025

Physician Assistant Dr. Michael Asbach addresses workforce solutions in psychiatry, from PA training and autonomous collaboration models to recent UK policy debates. Learn how interdisciplinary teams can expand access,…
,
JCP
Psychosocial Interventions and Functional Recovery in Schizophrenia
Academic Highlights

December 17, 2025

A consensus panel of experts reviewed the evidence base for use of psychosocial interventions in schizophrenia and provides practical recommendations for optimizing functional recovery.
, , , et al
JCP
Gestational Exposure to Antidepressants and Neurodevelopmental Disorders in Offspring
Clinical and Practical Psychopharmacology

December 17, 2025

This article reviews 2 meta-analyses and 3 more recent observational studies on gestational exposure to antidepressants and the risk of neurodevelopmental disorders in offspring.
JCP
Fluctuating ADHD Across the Lifespan with Margaret Sibley, PhD
Podcast

December 16, 2025

Dr. Margaret Sibley discusses fluctuating ADHD across the lifespan, insights from the MTA study, and what evolving symptom patterns mean for clinical care.
,
JCP
Valproic Acid Use in Females of Reproductive Age
Original Research

December 15, 2025

Approximately 1 in 5 valproic acid (VPA) prescriptions between 2017 to 2022 were prescribed to females of reproductive age. Only 14% of females of reproductive age using VPA were…
, , , et al
JCP
Obstetric Outcomes of Oral Versus Long-Acting Antipsychotics
Original Research

December 10, 2025

Similar rates of gestational diabetes, eclampsia, preeclampsia, and maternal hypertensive disorders were observed with long-acting injectable and oral second-generation antipsychotics.
, ,
JCP
HIV Diagnosis and PrEP Prescription in Commercially Insured Persons with Bipolar Disorder
Original Research

December 8, 2025

PrEP use among commercially insured people with bipolar disorder was critically low, with fewer than 1% prescribed PrEP.
, ,

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe